🇺🇸 FDA
Patent

US 9206421

Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene

granted A61KA61K31/713A61P

Quick answer

US patent 9206421 (Lipid formulated compositions and methods for inhibiting expression of serum amyloid A gene) held by Alnylam Pharmaceuticals, Inc. expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Dec 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/713, A61P, A61P1/00, A61P1/04